Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN: Brensocatib in Non-Cystic Fibrosis Bronchiectasis
2020-003688-25Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brensocatib in bronchiectasis (3 arms), sponsored by Insmed Incorporated. Primary endpoint: Rate of adjudicated pulmonary exacerbations over 52-week treatment. Started Oct 2020; status: completed.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2020-003688-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003688-25.